J. Pogue

S. Yusuf, J. Bosch, G. Dagenais, 2003, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

Direct-acting oral anticoagulants: the brain gets a break.

J. Pogue, J. Eikelboom, R. Hart, 2013, JAMA neurology.

ACTIVE W Substudy Patients Taking Oral Anticoagulation or Combined Antiplatelet Therapy: An Incidence of Stroke in Paroxysmal Versus Sustained Atrial Fibrillation in

S. Yusuf, J. Pogue, J. Healey, 2011 .

The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis

S. Yusuf, G. Dagenais, J. Pogue, 2005, Diabetologia.

Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease.

Salim Yusuf, Janice Pogue, Qilong Yi, 2005, American heart journal.

Telmisartan in high-risk patients intolerant of ACE inhibitors – Authors' reply

S. Yusuf, J. Pogue, C. Anderson, 2009, The Lancet.

Clonidine in patients undergoing noncardiac surgery.

G. Guyatt, D. Cook, K. Leslie, 2014, The New England journal of medicine.

Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial.

Sunil V. Rao, S. Yusuf, D. Xavier, 2010, JAMA.

Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.

S. Yusuf, J. Pogue, R. Diaz, 2010, The New England journal of medicine.

Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs

S. Yusuf, J. Pogue, S. Walter, 2009, Clinical trials.

Response to letter regarding article, "Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study".

J. Le Heuzey, S. Yusuf, J. Pogue, 2014, Circulation.

Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment.

S. Yusuf, P. Pais, J. Pogue, 2010, American heart journal.

IN THE LITERATURE Is Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Combination Therapy Better Than Monotherapy and Safe in Patients With CKD?

S. Yusuf, J. Pogue, 2009 .

Effect of angiotensin‐converting enzyme inhibition on functional class in patients with left ventricular systolic dysfunction—a meta‐analysis

M. Pfeffer, S. Yusuf, J. Pogue, 2006, European journal of heart failure.

Monitoring the ACTIVE-W trial: some issues in monitoring a noninferiority trial.

J. Pogue, J. Marler, D. Wyse, 2008, American heart journal.

Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy.

S. Yusuf, J. Bosch, G. Dagenais, 2002, Diabetes care.

Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study.

S. Yusuf, Á. Avezum, R. Peters, 2008, European heart journal.

A Risk Assessment Tool Incorporating New Biomarkers for Cardiovascular Events in Acute Coronary Syndromes: The Organization to Assess Strategies in Ischemic Syndromes (OASIS) Risk Score.

S. Yusuf, J. Pogue, S. Mehta, 2016, The Canadian journal of cardiology.

Effects of blood pressure and lipid lowering on cognition

S. Yusuf, J. Bosch, G. Dagenais, 2019, Neurology.

Cardiovascular Risk in Patients with Early Renal Insufficiency

S. Yusuf, J. Pogue, E. Lonn, 2002, American Journal of Cardiovascular Drugs.

Effect of Telmisartan on Renal Outcomes

Lars E. Rydn, S. Yusuf, G. Dagenais, 2009, Annals of Internal Medicine.

Increased cardiovascular risk after pre‐eclampsia in women with dysglycaemia

S. Yusuf, J. Pogue, E. Lonn, 2013, Diabetic medicine : a journal of the British Diabetic Association.

Rationale and Design of a Large Study to Evaluate the Renal and Cardiovascular Effects of an ACE Inhibitor and Vitamin E in High-Risk Patients With Diabetes: The MICRO-HOPE Study

S. Yusuf, J. Bosch, J. Pogue, 1996, Diabetes Care.

Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study.

S. Yusuf, R. McKelvie, J. Pogue, 1997, The Canadian journal of cardiology.

Canadian-led capacity-building in biostatistics and methodology in cardiovascular and diabetes trials: the CANNeCTIN Biostatistics and Methodological Innovation Working Group

S. Yusuf, J. Pogue, J. Cairns, 2011, Trials.

Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): a randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes initially treated with

Sunil V. Rao, S. Yusuf, D. Xavier, 2010, American heart journal.

Relationship of glucose and insulin levels to the risk of myocardial infarction: a case-control study.

S. Yusuf, P. Pais, J. Pogue, 1999, Journal of the American College of Cardiology.

Impact of ramipril on the circadian periodicity of acute myocardial infarction.

S. Yusuf, G. Dagenais, J. Pogue, 2006, The American journal of cardiology.

Beta-blocker therapy for congestive heart failure: a systemic overview and critical appraisal of the published trials.

S. Yusuf, Á. Avezum, J. Pogue, 1998, The Canadian journal of cardiology.

Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study.

S. Yusuf, J. Bosch, G. Dagenais, 2004, Kidney international.

Effects of Vitamin E on Cardiovascular and Microvascular Outcomes in High-Risk Patients With Diabetes

Gerstein, S. Yusuf, J. Bosch, 2002 .

Rationale and design of the Investigation of the Management of Pericarditis (IMPI) trial: a 2 × 2 factorial randomized double-blind multicenter trial of adjunctive prednisolone and Mycobacterium w immunotherapy in tuberculous pericarditis.

S. Yusuf, J. Bosch, J. Pogue, 2013, American heart journal.

Primary angioplasty compared with thrombolytic therapy for acute myocardial infarction.

S. Yusuf, J. Pogue, 1997, JAMA.

Venous thromboembolism in association with features of the metabolic syndrome.

S. Yusuf, J. Pogue, E. Lonn, 2007, QJM : monthly journal of the Association of Physicians.

Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study

Salim Yusuf, Janice Pogue, S. Yusuf, 2003, Circulation.

Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE)

J. Pogue, J. Healey, S. Connolly, 2015, The Lancet.

The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes.

J. Pogue, E. Lonn, H. Gerstein, 2004, Diabetes care.

Defibrillation testing and clinical outcomes after implantable cardioverter-defibrillator implantation in patients in atrial fibrillation at the time of implant: An analysis from the SIMPLE trial.

J. Pogue, J. Healey, S. Connolly, 2019, Heart rhythm.

A comparison of practice patterns for acute myocardial infarction between hospitals in Canada and India.

P. Pais, J. Pogue, Sonia S Anand, 1997, Indian heart journal.

Attributable Risk Function with Clustered Survival Data

J. Pogue, C. Xie, Xuewen Lu, 2013 .

Effects of the angiotensin receptor blocker, telmisartan, on cardiovascular events in high-risk patients intolerant to ACE-inhibitors. Erratum of Vol 372(9644):1174-83

S. Yusuf, J. Pogue, C. Anderson, 2008 .

Reevaluation by high-performance liquid chromatography: clinical significance of microalbuminuria in individuals at high risk of cardiovascular disease in the Heart Outcomes Prevention Evaluation (HOPE) Study.

S. Yusuf, J. Pogue, H. Gerstein, 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Neuraxial block, death and serious cardiovascular morbidity in the POISE trial.

K. Leslie, J. Pogue, J. Sear, 2013, British journal of anaesthesia.

Relationship of Anti-60 kDa Heat Shock Protein and Anti-Cholesterol Antibodies to Cardiovascular Events

S. Yusuf, J. Pogue, Mahavir Singh, 2002, Circulation.

SAFETY AND EFFICACY OF AGGRESSIVE BLOOD PRESSURE LOWERING AMONG PATIENTS WITH DIABETES: SUBGROUP ANALYSES FROM THE ONTARGET TRIAL

S. Yusuf, J. Pogue, P. Gao, 2009 .

Effect of clopidogrel added to aspirin in patients with atrial fibrillation.

Salim Yusuf, Marc Pfeffer, Janice Pogue, 2009, The New England journal of medicine.

Clopidogrel in Atrial Fibrillation: Is There Any Justification Now in the Era of New Anticoagulants?

P. Kirchhof, S. Ernst, B. Prendergast, 2012 .

Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.

S. Yusuf, J. Pogue, M. Flather, 2000, European heart journal.

Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial.

S. Yusuf, R. Peters, J. Pogue, 2006, JAMA.

Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial

Denis Xavier, Gordon Guyatt, Salim Yusuf, 2008, The Lancet.

Randomized Comparison of the Effects of Two Doses of Dabigatran Etexilate on Clinical Outcomes Over 4.3 Years : Results of the Rely-Able Double-Blind Randomized Trial

S. Yusuf, J. Pogue, M. Ezekowitz, 2012 .

Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies

S. Yusuf, Irina Chazova, J. Pogue, 2011, The Lancet Neurology.

Aspirin in patients undergoing noncardiac surgery.

G. Guyatt, D. Cook, K. Leslie, 2014, The New England journal of medicine.

Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial

S. Yusuf, Á. Avezum, J. Pogue, 2015, The Lancet.

Mo1999 How Often Does Major Gastrointestinal Bleeding in Patients Receiving Warfarin or Dabigatran Uncover Cancer? The U.S. Experience From the RELY Trial

S. Yusuf, J. Pogue, M. Ezekowitz, 2015 .

Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People With Impaired Glucose Tolerance or Impaired Fasting Glucose

S. Yusuf, J. Bosch, G. Dagenais, 2008, Diabetes Care.

Vitamin E supplementation and cardiovascular events in high-risk patients.

S. Yusuf, J. Bosch, G. Dagenais, 2000, The New England journal of medicine.

Abstract 4585: Efficacy and Safety of Clopidogrel in Acute Coronary Syndrome Patients at High Risk of Bleeding: Data from the CURE Trial

S. Yusuf, J. Pogue, S. Mehta, 2008 .

Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial

S. Yusuf, J. Bosch, J. Pogue, 2004, Diabetologia.

Irbesartan in patients with atrial fibrillation.

M. Pfeffer, S. Yusuf, J. Pogue, 2011, The New England journal of medicine.

Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis.

S. Yusuf, J. Bosch, J. Pogue, 2014, The New England journal of medicine.

Use of ramipril in preventing stroke: double blind randomised trial

J. Bosch, J. Pogue, E. Lonn, 2002, BMJ : British Medical Journal.

Net Clinical Benefit of Adding Clopidogrel to Aspirin Therapy in Patients With Atrial Fibrillation for Whom Vitamin K Antagonists Are Unsuitable

R. de Caterina, S. Yusuf, J. Pogue, 2011, Annals of Internal Medicine.

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial

M. Pfeffer, S. Yusuf, J. Pogue, 2006, The Lancet.

Prognostic utility and characterization of cell-free DNA in patients with severe sepsis

D. Cook, J. Pogue, D. Dwivedi, 2012, Critical Care.

Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators.

S. Yusuf, R. McKelvie, J. Pogue, 1999, Circulation.

Homocysteine lowering with folic acid and B vitamins in vascular disease.

S. Yusuf, C. Held, J. Pogue, 2006, The New England journal of medicine.

Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range

S. Yusuf, J. Pogue, J. Healey, 2008, Circulation.

Cognitive Function and Anticoagulation Control in Patients With Atrial Fibrillation

M. Pfeffer, S. Yusuf, J. Pogue, 2010, Circulation. Cardiovascular quality and outcomes.

Strengths and limitations of meta-analysis: larger studies may be more reliable.

S. Yusuf, J. Pogue, M. Flather, 1997, Controlled clinical trials.

Characteristics and Short-Term Prognosis of Perioperative Myocardial Infarction in Patients Undergoing Noncardiac Surgery

Denis Xavier, Gordon Guyatt, Salim Yusuf, 2011, Annals of Internal Medicine.

Nitrous Oxide and Serious Morbidity and Mortality in the POISE Trial

K. Leslie, J. Pogue, P. Myles, 2013, Anesthesia and analgesia.

Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial.

S. Yusuf, J. Bosch, G. Dagenais, 2005, JAMA.

Blood-pressure reduction and cardiovascular risk in HOPE study

Salim Yusuf, Peter Sleight, Janice Pogue, 2001, The Lancet.

Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease.

S. Yusuf, J. Bosch, G. Dagenais, 2016, The New England journal of medicine.

Dabigatran and Warfarin in Vitamin K Antagonist–Naive and –Experienced Cohorts With Atrial Fibrillation

S. Yusuf, J. Pogue, M. Ezekowitz, 2010, Circulation.

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial

Salim Yusuf, Janice Pogue, S. Yusuf, 2010, The Lancet.

Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation

S. Yusuf, J. Pogue, S. Connolly, 2007, Circulation.

The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study

H. Heidbuchel, J. Le Heuzey, S. Yusuf, 2013, Circulation.

With Atrial Fibrillation (RELY-ABLE) Study The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients

H. Heidbuchel, S. Yusuf, Jun Zhu, 2013 .

Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation.

S. Yusuf, J. Pogue, M. Ezekowitz, 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W.

R. de Caterina, S. Yusuf, J. Pogue, 2010, European heart journal.

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial

S. Yusuf, L. Piegas, A. Parkhomenko, 2008, The Lancet.

Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy.

Salim Yusuf, Janice Pogue, Marc A Pfeffer, 2007, Journal of the American College of Cardiology.

Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study.

S. Yusuf, G. Dagenais, J. Pogue, 2007, American heart journal.

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

S. Yusuf, G. Dagenais, J. Pogue, 2008, The Lancet.

Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized Trial

S. Yusuf, J. Bosch, J. Pogue, 2001, Annals of Internal Medicine.

Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial

G. Guyatt, M. Turiel, S. Yusuf, 2018, The Lancet.

Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk: The Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE-W)

R. de Caterina, M. Pfeffer, S. Yusuf, 2008, Stroke.

Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation

S. Yusuf, Á. Avezum, L. Piegas, 1998, The Lancet.

Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group.

R. Collins, M. Pfeffer, S. Yusuf, 1998, Circulation.

DABIGATRAN VERSUS WARFARIN IN ATRIAL FIBRILLATION PATIENTS WITH LOW, MODERATE AND HIGH CHADS2 SCORE: A RE-LY SUBGROUP ANALYSIS

S. Yusuf, J. Pogue, M. Ezekowitz, 2010 .

Comparative Impact of Multiple Biomarkers and N-Terminal Pro-Brain Natriuretic Peptide in the Context of Conventional Risk Factors for the Prediction of Recurrent Cardiovascular Events in the Heart Outcomes Prevention Evaluation (HOPE) Study

S. Yusuf, J. Pogue, E. Lonn, 2006, Circulation.

Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial

J. Pogue, S. Connolly, E. Themeles, 2016, European stroke journal.

Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data

R. Califf, S. Yusuf, J. Pogue, 2002, The Lancet.

Risk factors for acute myocardial infarction in Indians: a case-control study

Salim Yusuf, S. Yusuf, P. Pais, 1996, The Lancet.

Effect of ramipril on the incidence of diabetes.

S. Yusuf, J. Bosch, G. Dagenais, 2006, The New England journal of medicine.

Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial.

Jun Zhu, Changchun Xie, Denis Xavier, 2005, JAMA.

Effect of comorbidities on outcomes and angiotensin converting enzyme inhibitor effects in patients with predominantly left ventricular dysfunction and heart failure

S. Yusuf, J. Pogue, M. Böhm, 2014, European journal of heart failure.

Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation: Incidence, Risk Factors, and Outcomes

S. Yusuf, J. Pogue, M. Ezekowitz, 2015, Circulation.

Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Int

S. Yusuf, J. Pogue, C. Anderson, 2004, American heart journal.

Ramipril and the development of diabetes.

S. Yusuf, J. Bosch, J. Pogue, 2001, JAMA.

Stroke in Relation to Cardiac Procedures in Patients With Non–ST-Elevation Acute Coronary Syndrome: A Study Involving >18 000 Patients

S. Yusuf, J. Pogue, A. Budaj, 2001, Circulation.

Safety outcomes in meta-analyses of phase 2 vs phase 3 randomized trials: Intracranial hemorrhage in trials of bolus thrombolytic therapy.

S. Yusuf, J. Pogue, S. Mehta, 2001, JAMA.

Efficacy of hirudin in reducing cardiovascular events in patients with acute coronary syndrome undergoing early percutaneous coronary intervention.

S. Yusuf, B. Lewis, J. Pogue, 2002, European heart journal.

Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina

S. Yusuf, M. Keltai, B. Lewis, 2001 .

Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators.

S. Yusuf, M. Keltai, J. Varigos, 2001, Journal of the American College of Cardiology.

The Organization to Assess Strategies for Ischemic Syndromes (OASIS) registry in patients with unstable angina.

S. Yusuf, Á. Avezum, M. Keltai, 1999, The American journal of cardiology.

Referrals in acute coronary events for CARdiac catheterization: The RACE CAR trial.

J. Pogue, Sonia S Anand, J. Velianou, 2010, The Canadian journal of cardiology.

Statistical Approaches to Improving Trial Efficiency and Conduct

S. Yusuf, J. Pogue, P. Devereaux, 2014 .

Effects of off-pump and on-pump coronary-artery bypass grafting at 1 year.

S. Yusuf, L. Piegas, J. Pogue, 2013, The New England journal of medicine.

TESTING FOR TREATMENT HETEROGENEITY BETWEEN THE INDIVIDUAL OUTCOMES WITHIN A COMPOSITE OUTCOME

J. Pogue, 2012 .

Testing for heterogeneity among the components of a binary composite outcome in a clinical trial

S. Yusuf, J. Pogue, P. Devereaux, 2010, BMC medical research methodology.

Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).

S. Yusuf, J. Pogue, P. Gao, 2012, Journal of the American College of Cardiology.

Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients.

S. Yusuf, J. Bosch, G. Dagenais, 2007, European heart journal.

Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials

S. Yusuf, G. Dagenais, J. Pogue, 2006, The Lancet.

Long-Term Effects of Ramipril on Cardiovascular Events and on Diabetes: Results of the HOPE Study Extension

S. Yusuf, J. Bosch, G. Dagenais, 2005, Circulation.

Prognostic usefulness of left ventricular hypertrophy by electrocardiography in patients with atrial fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study).

S. Yusuf, J. Pogue, M. Ezekowitz, 2014, The American journal of cardiology.

Reduction of Cardiovascular Risk by Regression of Electrocardiographic Markers of Left Ventricular Hypertrophy by the Angiotensin-Converting Enzyme Inhibitor Ramipril

S. Yusuf, J. Bosch, J. Pogue, 2001, Circulation.

Prospective long-term evaluation of Optim-insulated (Riata ST Optim and Durata) implantable cardioverter-defibrillator leads.

J. Pogue, J. Healey, S. Connolly, 2014, Heart rhythm.

Systolic and Diastolic Blood Pressure Changes in Relation With Myocardial Infarction and Stroke in Patients With Coronary Artery Disease

S. Yusuf, J. Pogue, P. Gao, 2015, Hypertension.

Modifiable lifestyle and social factors affect chronic kidney disease in high-risk individuals with type 2 diabetes mellitus.

G. Heinze, S. Yusuf, J. Pogue, 2015, Kidney international.

Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review

R. Collins, M. Pfeffer, S. Yusuf, 2002, The Lancet.

Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators.

S. Yusuf, J. Pogue, B. Hoogwerf, 2000, Diabetes care.

Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators.

S. Yusuf, J. Pogue, B. Hoogwerf, 2000, Diabetes care.

The Family Atherosclerosis Monitoring In earLY life (FAMILY) study: rationale, design, and baseline data of a study examining the early determinants of atherosclerosis.

S. Yusuf, J. Pogue, K. Teo, 2009, American heart journal.

Community health worker-based intervention for adherence to drugs and lifestyle change after acute coronary syndrome: a multicentre, open, randomised controlled trial.

S. Yusuf, D. Xavier, P. Pais, 2016, The lancet. Diabetes & endocrinology.

Editorial See P 787 Clinical Perspective on P 803

S. Yusuf, J. Pogue, M. Ezekowitz, 2022 .

Elevated lipoprotein(a) levels in South Asians in North America.

J. Pogue, S. Yusuf, Sonia S Anand, 1998, Metabolism: Clinical and Experimental.

Cost Implications of the Use of Ramipril in High-Risk Patients Based on the Heart Outcomes Prevention Evaluation (HOPE) Study

S. Yusuf, J. Pogue, A. Gafni, 2003 .

Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics.

S. Yusuf, J. Bosch, G. Dagenais, 2016, The Canadian journal of cardiology.

Identifying Novel Biomarkers for Cardiovascular Events or Death in People With Dysglycemia

S. Yusuf, J. Pogue, H. Gerstein, 2015, Circulation.

Functional capacity in patients with congestive heart failure.

S. Yusuf, R. McKelvie, J. Pogue, 2000, Journal of cardiac failure.

, Janice and Stroke in Patients With Coronary Artery Disease Systolic and Diastolic Blood Pressure Changes in Relation With Myocardial Infarction

S. Yusuf, J. Pogue, P. Gao, 2014 .

Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.

S. Yusuf, J. Bosch, G. Dagenais, 2016, The New England journal of medicine.

Data Monitoring in the Randomized Evaluation of Strategies for Left Ventricular Dysfunction Pilot Study: When Reasonable People Disagree

S. Yusuf, J. Pogue, 2006 .

Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: the Heart Outcomes Prevention Evaluation (HOPE)-2 trial.

S. Yusuf, J. Bosch, J. Pogue, 2006, The Canadian journal of cardiology.

Weighted Multiple Testing Correction for Correlated Binary Endpoints

Xuewen Lu, Changchun Xie, Ding-Geng Chen, 2013, Commun. Stat. Simul. Comput..

Study design and baseline characteristics of the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E: SECURE.

S. Yusuf, J. Pogue, E. Lonn, 1996, The American journal of cardiology.

Incidence of Diabetes Following Ramipril or Rosiglitazone Withdrawal

S. Yusuf, J. Bosch, G. Dagenais, 2011, Diabetes Care.

Predictors, Prognosis, and Management of New Clinically Important Atrial Fibrillation After Noncardiac Surgery: A Prospective Cohort Study

D. Cook, S. Yusuf, D. Xavier, 2017, Anesthesia and analgesia.

Clinician-trialist rounds: 19. Faux pas or fraud? Identifying centers that have fabricated their data in your multi-center trial

D. Sackett, J. Pogue, 2014, Clinical trials.

Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination, in high risk patients: The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telm

S. Yusuf, J. Pogue, C. Anderson, 2004 .

Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation.

S. Yusuf, J. Bosch, J. Pogue, 1996, Diabetes Care.

Causes of Death and Influencing Factors in Patients With Atrial FibrillationClinical Perspective

S. Yusuf, J. Pogue, M. Ezekowitz, 2013 .

Steroids In caRdiac Surgery (SIRS) trial: acute kidney injury substudy protocol of an international randomised controlled trial

S. Yusuf, J. Pogue, A. Garg, 2014, BMJ Open.

Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study.

S. Yusuf, J. Pogue, A. Gafni, 2003, Circulation.

The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease.

S. Yusuf, M. Keltai, B. Lewis, 2000, European heart journal.

Effect of Telmisartan on Renal Outcomes: A Randomized Trial

S. Yusuf, G. Dagenais, J. Pogue, 2010 .

The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study

S. Yusuf, D. Xavier, P. Pais, 2009, Nature Clinical Practice Cardiovascular Medicine.

Reviparin in Acute Myocardial Infarction—Reply

S. Yusuf, J. Pogue, C. Xie, 2005 .

Tackling NCD in LMIC: Achievements and Lessons Learned From the NHLBI-UnitedHealth Global Health Centers of Excellence Program.

L. Smeeth, E. Vartiainen, D. Xavier, 2016, Global heart.

Neuraxial Block, Death, and Serious Cardiovascular Morbidity in the Perioperative Ischemia Evaluation Trial

K. Leslie, J. Pogue, P. Myles, 2014 .

Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial.

Li-sheng Liu, P. Pais, J. Pogue, 2005, Journal of the American Medical Association (JAMA).

Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy.

S. Yusuf, Á. Avezum, J. Pogue, 2015, The New England journal of medicine.

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

J. Pogue, S. Yusuf, P. Sleight, 2000, The New England journal of medicine.

Beta-blocker therapy for congestive heart failure: a systemic overview and critical appraisal of the published trials.

J. Pogue, Á. Avezum, Ross T. Tsuyuki, 1998, The Canadian journal of cardiology.

Clonidine in patients undergoing noncardiac surgery.

G. Guyatt, D. Cook, K. Leslie, 2014, The New England journal of medicine.

Vitamin E supplementation and cardiovascular events in high-risk patients.

J. Pogue, S. Yusuf, P. Sleight, 2000 .

Systolic and Diastolic Blood Pressure Changes in Relation With Myocardial Infarction and Stroke in Patients With Coronary Artery Disease

S. Yusuf, J. Pogue, P. Gao, 2015, Hypertension.

Abstract 4585: Efficacy and Safety of Clopidogrel in Acute Coronary Syndrome Patients at High Risk of Bleeding: Data from the CURE Trial

S. Yusuf, J. Pogue, S. Mehta, 2008 .

Dabigatran versus warfarin in patients with atrial fibrillation.

S. Yusuf, Jun Zhu, D. Xavier, 2009, The New England journal of medicine.